In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioMarin Pharmaceutical Inc.

https://www.biomarin.com/

Latest From BioMarin Pharmaceutical Inc.

Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’

Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.

Sales & Earnings Commercial

US FDA Looks To Assure Advisory Committees' Subject Expertise With More Temporary Members

Reform efforts in CDER include ensuring expertise is specific to the issues being discussed, which may mean more temporary voting members on advisory committees.

Prescription To OTC Switch Advisory Committees

Keeping Track: Entasis’ Antibiotic Xacduro, Two Opioid Misuse Therapies Clear US FDA; Pfizer’s Paxlovid Makes It Official

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Intercept’s Ocaliva: ‘Dangling’ PBC Indication At Risk As Near-Term NASH Approval Looks Unlikely

Accelerated approval for primary biliary cholangitis in 2016 came with three postmarketing requirements, but studies were terminated early; firm working toward sNDA submission in 2023 for regular approval, but US FDA says reports already are overdue and it expects to take PBC indication back to an adcomm.

Review Pathway Post Market Regulation & Studies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Liposomes
  • Other Names / Subsidiaries
    • Huxley Pharmaceuticals, Inc.
    • LEAD Therapeutics, Inc.
    • Prosensa Holding N.V
    • Zacharon Pharmaceuticals, Inc.
    • ZyStor Therapeutics, Inc.
UsernamePublicRestriction

Register